Evotec has acquired a new long-term strategic investor and received fresh funds from an existing shareholder to finance an expansion of its drug discovery portfolio and its geographical footprint in Europe and the US. The new investor is the Mubadala Investment Company PJSC, a sovereign wealth fund wholly owned by the government of Abu Dhabi. The existing investor is Novo Holdings A/S. Together they have purchased 11.5 million Evotec shares for €250 million, of which €200 represents the Mubadala investment and €50 million, the investment by Novo.
